Identification of molecular mechanisms responsible for aseptic chronic prostatitis may lead to tailored anti-inflammatory treatments (e.g., Takinib), while a better understanding of the regulatory pathways controlling PSA can contribute to a more accurate interpretation of tumor response to therapy. This evidence concerns the gene KLK3 and prostatitis.